Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study

  • Boluda, Blanca
  • Rodriguez-Veiga, Rebeca
  • Sargas, Claudia
  • Ayala, Rosa
  • Larráyoz, María José
  • Chillón, María Carmen
  • Soria-Saldise, Elena
  • Bilbao, Cristina
  • Prados de la Torre, Esther
  • Navarro, Irene
  • Martínez-Cuadrón, David
  • Gil, Cristina
  • Bernal, Teresa
  • Bergua, Juan
  • Algarra, Lorenzo
  • Tormo, Mar
  • Martínez-Sánchez, Pilar
  • Carrillo-Cruz, Estrella
  • Serrano, Josefina
  • Alonso-Domínguez, Juan Manuel
  • García, Raimundo.
  • Amigo, María Luz
  • Herrera-Puente, Pilar
  • Sayas, María-José
  • Lavilla-Rubira, Esperanza
  • García-Pérez, María José
  • Morán, Julia
  • Pérez-Santaolalla, Esther
  • Alonso-Vence, Natalia
  • Oliva, Ana
  • López, Juan Antonio
  • Barrios, Manuel
  • García-Fortes, María
  • Olave, María Teresa
  • Labrador, Jorge
  • Martínez-López, Joaquín
  • Calasanz, Mª Jose
  • García-Sanz, Ramón
  • Pérez-Simón, José A.
  • Gómez-Casares, María T
  • Sánchez-García, Joaquín
  • Mendizabal, Yolanda
  • Barragán, Eva
  • Montesinos, Pau
(This article belongs to the Special Issue New Approaches in Leukemia)., The authors would like to thank all the PETHEMA institutions and clinicians, PETHEMA data managers for data collection and management, and the central laboratory staff for sample management. A complete list of the institutions and clinicians participating in the PETHEMA epidemiologic registry of acute myeloid leukemia appears in the Supplementary Materials “Appendix”., [Simple Summary] This PETHEMA PCR-LMA study aimed to evaluate whether mutations detected by NGS (VAF cut-off of ≥5%) correlate with NPM1, FLT3-ITD, FLT3-TKD, IDH1, and IDH2 mutations detected using conventional PCR (analytical sensitivity 3%) in a nationwide network of seven reference laboratories. Between 2019 and 2021, 1685 adult acute myeloid leukemia (AML) patients with at least one centralized sample (NGS or PCR) at primary diagnosis or relapse/refractory episode were included, and 1288 paired NGS/PCR samples were analyzed. Considering PCR the gold-standard, for NPM1 NGS sensitivity was 98.5% and specificity 98.9%, for FLT3-ITD 73.8% and 99.6%, for FLT3-TKD 84.5% and 99.3%, for IDH1 98.7% and 98.7%, and for IDH2 99.1% and 97.7%, respectively. Overall, median days from sample reception until report were 7 for PCR and 28 for NGS. This study shows high concordance between NPM1 and IDH results using PCR and NGS. However, sensible important discrepancies are observed for FLT3 mutations., [Abstract] Background/Objectives: This PETHEMA PCR-LMA study aimed to evaluate whether mutations detected by NGS (VAF cut-off of ≥5%) correlate with NPM1, FLT3-ITD, FLT3-TKD, IDH1, and IDH2 mutations detected using conventional PCR (analytical sensitivity 3%) in a nationwide network of seven reference laboratories. Methods: Between 2019 and 2021, 1685 adult AML patients with at least one centralized sample (NGS or PCR) at primary diagnosis or relapse/refractory episode were included. Results: During this period, 1288 paired NGS/PCR samples (1094 at diagnosis, 103 at relapse and 88 at refractoriness) were analyzed. Considering PCR the gold-standard, for NPM1 NGS sensitivity was 98.5% and specificity 98.9%, for FLT3-ITD 73.8% and 99.6%, for FLT3-TKD 84.5% and 99.3%, for IDH1 98.7% and 98.7%, and for IDH2 99.1% and 97.7%, respectively. Overall concordance rate of positive results between NGS (and PCR was 95% (262/276) for NPM1, 72% (149/206) for FLT3-ITD, 74% (49/66) for FLT3-TKD, 87% (77/89) for IDH1 and 84% (107/127) for IDH2. Overall, median days from sample reception until report were 7 for PCR and 28 for NGS. Conclusions: This study shows high concordance between NPM1 and IDH results using PCR and NGS. However, sensible important discrepancies are observed for FLT3 mutations. In our context, rapid screening for these druggable mutations should be performed by conventional PCR., This study was supported in part by Novartis and PMP22/00069, PI18/01340, PI18/01946 and PI21/01705 Instituto de Salud Carlos III grants., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories

  • Coucelo, Margarida
  • Sargas, Claudia
  • Ayala, Rosa
  • Larráyoz, María José
  • Chillón, María Carmen
  • Soria, Elena
  • Bilbao, Cristina
  • Prados de la Torre, Esther
  • Amorim, Maria Luis
  • Mirales, Alberto
  • Cionfrini, Antonia
  • Simões, Ana T.
  • Oliveira, Ana C.
  • Rodríguez-Veiga, Rebeca
  • Lloret-Madrid, Pilar
  • Mendizábal, Yolanda
  • Botella, Carmen
  • Bernal, Teresa
  • Bergua, Juan
  • Algarra, Lorenzo
  • Tormo, Mar
  • Sarmento-Ribeiro, Ana Bela
  • Trigo, Fernanda
  • Cortesão, Emilia
  • Martínez-Sánchez, Pilar
  • Serrano, Josefina
  • Alonso-Domínguez, Juan Manuel
  • García, Raimundo
  • Amigo, María Luz
  • Herrera-Puente, Pilar
  • Sayas, María-José
  • Abuín, Aitor
  • Martínez-López, Joaquín
  • Calasanz, María José
  • García-Sanz, Ramón
  • Gutiérrez, Norma
  • Pérez-Simón, José A.
  • Gómez-Casares, M. Teresa
  • Sánchez-García, Joaquín
  • Montesinos, Pau
  • Barragán, Eva
  • PETHEMA Group
The rapid and accurate laboratory identification of targetable therapeutic genes, together with the implementation of measurable residual disease (MRD) based decision is essential for optimal clinical management in acute myeloid leukemia (AML). The PETHEMA (Programa Español de Tratamientos en Hematología) cooperative group comprises nine laboratories that perform centralized molecular studies by conventional PCR and Real-time quantitative PCR (RT-qPCR) for AML patients. With the aim to validate laboratories performances, we conducted three rounds of interlaboratory cross validation (ICV) for the quantification of CBFB::MYH11, RUNX1::RUNX1T1 and NPM1 and one round to determine the mutational status of NPM1, FLT3 (ITD and TKD2) IDH1 and IDH2. For RT-qPCR a total of 19 samples were tested and only 3 (15.8 %) failed to achieve 100 % concordance, corresponding to samples with low target gene mean ratios (ICV1-S4, ICV2-S1, ICV2-S6). For mutation detection in a total of 227 returned results, concordance rate ranged from 95 % to 100 %. FLT3-ITD and NPM1 mutation detection had 100 % concordant results. One false negative was reported for IDH2- R140 mutation and 4 false positives were detected: 2 FLT3-TKD2 and 2 IDH1-R132, likely reflecting differences in assay sensitivity. Overall, the results were highly satisfactory, particularly regarding MRD assessment, and highlighted key points for improvement, especially in baseline detection of FLT3-TKD2 and IDH1 mutations. This study represents the first collaborative initiative to evaluate performance of AML molecular targets within a laboratory network and underscores the importance of regular exercises to monitor performance, identify and resolve technical or interpretive discrepancies to ultimately ensure accurate clinical decision-making., This study was partially funded by the Instituto de Salud Carlos III, Spain: PMP22/00069, Peer reviewed